Cardiovascular health: the global challenge

Editorial

S A Waldman et al. Clin Pharmacol Ther. 2011 Oct.

. 2011 Oct;90(4):483-5.

doi: 10.1038/clpt.2011.213.

No abstract available

Comment in

Optimizing revascularization strategies in coronary artery disease for optimal benefit to patients.
Mangiacapra F, De Bruyne B, Wijns W, Bartunek J. Mangiacapra F, et al. Clin Pharmacol Ther. 2011 Oct;90(4):630-3. doi: 10.1038/clpt.2011.162. Epub 2011 Aug 31. Clin Pharmacol Ther. 2011. PMID: 21881563
From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020.
Kovacic JC, Fuster V. Kovacic JC, et al. Clin Pharmacol Ther. 2011 Oct;90(4):509-18. doi: 10.1038/clpt.2011.173. Epub 2011 Sep 7. Clin Pharmacol Ther. 2011. PMID: 21900892
Pharmacogenomics: application to the management of cardiovascular disease.
Johnson JA, Cavallari LH, Beitelshees AL, Lewis JP, Shuldiner AR, Roden DM. Johnson JA, et al. Clin Pharmacol Ther. 2011 Oct;90(4):519-31. doi: 10.1038/clpt.2011.179. Epub 2011 Sep 14. Clin Pharmacol Ther. 2011. PMID: 21918509 Free PMC article.
The impact of pharmacogenomics on the management of cardiac disease.
Pereira NL, Weinshilboum RM. Pereira NL, et al. Clin Pharmacol Ther. 2011 Oct;90(4):493-5. doi: 10.1038/clpt.2011.187. Epub 2011 Aug 10. Clin Pharmacol Ther. 2011. PMID: 21934720 Free PMC article.
The Achilles' heel of cardiovascular genetic testing: distinguishing pathogenic mutations from background genetic noise.
Landstrom AP, Ackerman MJ. Landstrom AP, et al. Clin Pharmacol Ther. 2011 Oct;90(4):496-9. doi: 10.1038/clpt.2011.192. Clin Pharmacol Ther. 2011. PMID: 21934721 Free PMC article.